Approval of the Standalone and Consolidated Financial Statements for the Second half year ended and year ended 31st March 2025 and the consideration of the Limited Review Report thereon ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved the standalone and consolidated audited financial statements for the half-year and year ended 31 March 2025. Statutory auditors CGSS & Associates LLP issued an unmodified (clean) opinion on both sets of results. Consolidated FY25 revenue grew 7.08% YoY to ₹1,003.8 Mn, while standalone revenue grew 6.2% YoY to ₹944.2 Mn. However, profitability was weak — consolidated EBITDA fell 21.9% YoY to ₹97.1 Mn with margin compressing to 9.7% (from 13.3%), and PAT dropped 33.6% YoY to ₹40.5 Mn. The company also reported a sharply negative operating cash flow of ₹(1,707.78) lakhs versus ₹330.94 lakhs in FY24, driven by a large increase in receivables. IPO funds of ₹29.95 crores were fully utilised in H1FY25 with no deviations. The Board recommended a dividend of ₹0.30 per share (3%) on a face value of ₹10, subject to shareholder approval. The auditor included an emphasis of matter paragraph regarding gratuity disclosure under AS-15, though the opinion remained unmodified.
For shareholders: a modest first dividend post-listing signals confidence, but the steep decline in profits and negative operating cash flow — despite revenue growth — point to margin pressure and working capital strain. FY26 guidance targets revenue of ₹130 Cr and EBITDA margin recovery to 11–13%, but near-term stock sentiment may be tempered by weak FY25 earnings.